Bone Biologics Corporation
Simbol: BBLG
NASDAQ
1.8001
USDTržna cena danes
-0.1011
Razmerje P/E
0.0004
Razmerje PEG
1.58M
Kapaciteta MRK
- 0.00%
Donos DIV
Bone Biologics Corporation (BBLG) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | -0.3 | -0.6 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.7 | 1 | 0 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.4 | 0 | 0.1 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | -0.8 | 0 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 0.5 | 2.5 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 0.8 | 2.5 | 0.1 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -80.9 | -72 | -70.5 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 83.8 | 77.9 | 77 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -3 | -7.5 | -6.7 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.3 | 0.2 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.1 | -0.2 | -0.3 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.8 | -0.4 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -1 | 0 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -2.2 | 0.5 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 5 | 4.4 | 6.9 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 1.1 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5 | 4.4 | 7.9 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -4.5 | 0.9 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 7.5 | 6.7 | 0 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -9.6 | -3.6 | -1.2 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -9.6 | -3.6 | -1.2 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 9.4 | -0.7 | 0 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | -9.4 | -3.7 | -1.1 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.2 | 0 | ||||||||||||||||
income-statement-row.row.net-income | 0 | -8.9 | 0.7 | -1.6 |
Pogosto zastavljeno vprašanje
Kaj je Bone Biologics Corporation (BBLG) skupna sredstva?
Bone Biologics Corporation (BBLG) skupna sredstva so 3737763.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.000.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -17.887.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.000.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.000.
Kaj je Bone Biologics Corporation (BBLG) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -8948731.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 0.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 9428303.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 0.000.